Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Oliver C CohenNicholas CounsellNeil RabinRakesh PopatRoger G OwenBilyana PopovaOliver SchofieldLaura Clifton-HadleyJanet Lyons-LewisAndy RawstronChristopher SpenceRuth M de TuteDerralynn HughesSally MoorePaul SmithKwee L YongPublished in: British journal of haematology (2018)